How Omico is making a difference
Why work with Omico?
Make your trials cheaper and faster to run.
Get access to 25,000 screened patients.
Identify the right patients and the right trials.
Draw on the knowledge and expertise of our network.
Finding new treatment paths for difficult-to-treat cancers
Omico’s landmark Precision Oncology Screening Platform Enabling Clinical Trials (PrOSPeCT) aims to open up new options for patients with difficult-to-treat, advanced and metastatic cancers.
Matching patients to biomarker-led clinical trials
Through our Cancer Screening Project (CaSP) we’re performing comprehensive genomic profiling for cancer patients with unmet clinical need to match them to clinical trials or other care pathways.
Matching molecular changes to targeted therapy
Our Molecular Screening and Therapeutics (MoST) study aims to characterise molecular changes in a patient’s cancer that may help to identify a targeted therapy.
Identifying genetic basis of cancer risk
We’re examining the genetic basis of inherited cancer with our Genetic Cancer Risk in the Young (RisC) study.
Improving surveillance of multi-organ cancer
Our Surveillance study in Multi-Organ Cancer-prone syndromes (SMOC+) study is investigating and evaluating the surveillance practices used for people at high risk of multi-organ cancer.